MedTrace Logo

Octreotide Acetate in Microspheres in Patients With Diabetic Retinopathy

NCT00131144 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 583

Last updated 2011-11-17

No results posted yet for this study

Summary

The most common ocular disease in patients with diabetes, diabetic retinopathy, is present in approximately 40% of diabetic patients; about 8% of diabetic patients have vision threatening diabetic retinopathy. Although intensive control of blood glucose has been shown to reduce the development and progression of diabetic retinopathy, intensive control of glucose is usually not achieved in clinical practice.

Conditions

Interventions

DRUG

Octreotide Acetate in Microspheres 20 mg

DRUG

Octreotide Acetate in Microspheres

DRUG

Placebo

Sponsors & Collaborators

Principal Investigators

  • Novartis Customer Information · East Hanover

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1999-11-30
Primary Completion
2005-12-31
Completion
2005-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00131144 on ClinicalTrials.gov